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pAbstract
Introduction: Adrenomedullin (ADM), a circulating vasodilatory peptide, plays
an important role in the development of sepsis-associated hemodynamic and
microcirculatory disorders. While administration of exogenous ADM had beneficial
effects in several septic animal models, elevated ADM concentrations are associated
with a bad outcome. This prompted us to test the effect of various anti-ADM
antibodies in a cecal ligation and puncture (CLP) mouse model.
Methods: To gain new potential compounds for the treatment or prevention of
septic shock we followed an alternative strategy to influence the ADM system:
High-affinity anti-ADM antibodies with different epitope specificities were developed
and their antagonist activity in vitro and their ability to reduce mortality in a CLP
mouse model were assessed.
Results: An anti-ADM antibody directed against the N-terminus substantially
increased the survival of mice in a CLP model (HR = 0.077 (CI = 0.0189 to 0.315),
p = 0.0004), whereas other antibodies with similar affinities but different epitope
specificities were much less potent. The efficacious antibody, in contrast to an
anti-C-terminal antibody, only partially inhibited ADM agonist activity in vitro.
Healthy mice were not negatively affected by the N-terminal antibody.
Conclusions: An anti-N-terminal ADM antibody, as opposed to antibodies with other
epitope specificities, strongly reduces mortality in CLP mice.
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Despite advances in supportive care, each year 750,000 people develop sepsis and
225,000 die in the USA alone, and the incidence of sepsis is rising at rates between
1.5% and 8% per year [1-3]. Sepsis is a complex and dynamic condition initiated by an
infectious stimulus and proceeding to an exaggerated systemic immune response [4,5].
Several approaches in the past two decades to improve sepsis-associated mortality by
novel therapies have had only limited only [6-10].
The peptide adrenomedullin (ADM) has been implicated in the development of
septic shock: It is important in initiating the hyperdynamic response during the early2013 Struck et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution
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transition from the hyperdynamic phase to the hypodynamic phase during the progression
of sepsis [11-14].
ADM comprises 52 amino acids and is secreted into the blood stream from a variety of
tissues [15-17]. ADM has multiple functions, the most prominent being its vasodilatory
activity. It acts on vascular smooth muscle cells and vascular endothelial cells by binding
to a G protein-coupled receptor system composed of the calcitonin receptor-like receptor
(CRLR) and an accessory protein (receptor activity-modifying protein (RAMP) 2 or 3) via
downstream cyclic adenosine monophosphate (cAMP) and NO signaling. In several
preclinical studies exogenous ADM reduced mortality from septic shock and multiple
organ failure (MOF) by reducing vascular hyperpermeability, preventing endothelial cell
dysfunction and down-regulating the inflammatory response [12,18-21].
Apparently, in contrast to the reported beneficial effects of ADM in sepsis, ADM has been
categorized as a cardiac depressant factor in sepsis: ADM (22-52), an ADM receptor antag-
onist, improved the contractility of myocytes isolated from lipopolysaccharide (LPS)-treated
rats. In addition, an anti-ADM antiserum improved the survival of LPS-treated rats [22].
Plasma levels of circulating ADM are relatively stable throughout various clinical
conditions [23]. The strongest elevations have been observed in severe sepsis and septic
shock, where increased ADM levels are associated with fatal outcome [24-26], suggesting
that excessively high concentrations of ADM can be detrimental. In the present study, we
assessed whether certain antibodies against ADM are potentially suitable therapeutic
compounds to reduce sepsis-associated mortality in a cecal ligation and puncture mouse
model, and how their efficacy in the animal model is associated with their affinities,
epitope specificities, and antagonist activities.Material and methods
Development of mouse monoclonal anti-ADM antibodies
Antipeptide antibodies were generated and selected by standard procedures (Unicus OHG,
Karlsburg, Germany): Peptides were synthesized, as listed in Table 1 (JPT Technologies
GmbH, Berlin, Germany). An additional N-terminal cysteine residue was added if no cyst-
eine was present within the selected ADM-derived sequence. The peptides were
conjugated to maleimide-activated bovine serum albumin (BSA). BALB/c mice were
immunized with 100 μg of peptide-BSA conjugate per animal at days 0 and 14Table 1 Overview on monoclonal anti-ADM antibodies and their characteristics





Kd (M) Maximal inhibition
in bioassay (%)
NT-M YRQSMNQGSRSNGCRFGTC 1-19 2a 5.8 × 10-9 24.0
MR-M CTFQKLAHQIYQ 19-31 1 5.9 × 10-9 61.7
CT-M CAPRNKISPQGY-NH2 Cys-40-50 2b 9.0 × 10
-9 102.1
NT-H YRQSMNNFQGLRSFGCRFGTC 1-21 1 1.6 × 10-8 25.5
MR-H CTVQKLAHQIYQ 21-32 1 2.0 × 10-9 74.4
CT-H CAPRSKISPQGY-NH2 Cys-42-52 1 1.1 × 10
-9 100.7
The antibodies were named according to their epitope specificities as follows: NT, anti-N-terminal region; MR, anti-midregion;
CT, anti-C-terminal region; and the suffixes M and H designate mouse and human ADM, respectively.
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(in 100 μL of incomplete Freund's adjuvant). Three days before the fusion, each
animal received 50 μg of the conjugate dissolved in 100 μL of saline, given as one
intraperitoneal and one intravenous injection. Splenocytes from the immunized
mice and cells of the myeloma cell line SP2/0 were fused with 1 mL of 50% polyethylene
glycol. After washing, the cells were seeded in 96-well cell culture plates. Hybridomas
were selected by growing in hypoxanthine-aminopterin-thymidine (HAT) medium
(RPMI-1640 culture medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with
20% fetal calf serum and HAT Supplement (Life Technologies, Grand Island, NY, USA)).
After 2 weeks, the HAT medium was replaced with HT medium for three passages
followed by returning to the normal cell culture medium. The cell culture supernatants
were primarily screened for antigen-specific IgG antibodies 3 weeks after fusion. The
positive tested microcultures were transferred into 24-well plates for propagation.
After retesting, the selected cultures were cloned and recloned using the limiting
dilution technique and the isotypes were determined. Monoclonal antibodies were
produced and purified by standard methods employing Protein A chromatography.
The antibody purities were >95% based on SDS gel electrophoresis analysis. Fab and F(ab)2
fragments were generated by standard procedures. For antibody nomenclature, see Table 1.Affinity constants
To determine the affinity of the antibodies to human and mouse ADM, respectively,
the association and dissociation kinetics of ADM binding to immobilized antibody was
determined by means of label-free surface plasmon resonance using a Biacore 2000
system (GE Healthcare Europe GmbH, Freiburg, Germany). Reversible immobilization
of the antibodies was performed using an anti-mouse Fc antibody covalently coupled in
high density to a CM5 sensor surface according to the manufacturer's instructions
(mouse antibody capture kit; GE Healthcare). Antibody binding kinetics were determined by
standard procedures, and affinity constants were calculated (Biaffin GmbH, Kassel, Germany).ADM bioassay
CHO-K1 cells expressing recombinant ADM receptor (CRLR + RAMP3 (FAST-027C;
Euroscreen S.A., Brussels, Belgium) grown in media without antibiotic prior to the
test were detached by gentle flushing with PBS-EDTA (5 mM EDTA), recovered by
centrifugation, and resuspended in assay buffer (5 mM KCl, 1.25 mM MgSO4, 124
mM NaCl, 25 mM HEPES, 13.3 mM glucose, 1.25 mM KH2PO4, 1.45 mM CaCl2,
0.5 g/L BSA). Dose-response curves were obtained in parallel with the reference
agonists human ADM and mouse ADM. After addition of the lysis buffer, cAMP
was measured with an HTRF kit according to the instructions of the manufacturer
(Cis-Bio International, Bagnols, France). The dose-dependent antagonist activity of
anti-ADM antibodies was determined in the presence of human ADM or mouse
ADM, respectively, either one at a predetermined concentration yielding 80% of
the maximal stimulation obtainable for the cAMP response: 6 μL of the reference
agonist (human (5.63 nM) or mouse (0.67 nM) ADM) was mixed with 6 μL of the
test samples at different antibody dilutions of 100, 20, 4, 0.8, and 0.16 μg/mL.
After incubation for 60 min at room temperature, 12 μL of cells (2,500 cells/well)
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cAMP was measured as described above. Antagonist activity of anti-ADM antibodies was
calculated as percentage of inhibition relative to the maximal inhibition obtainable with
the reference antagonist peptide ADM (22-52).Sepsis model (cecal ligation puncture)
Twelve- to fifteen-week-old male C57Bl/6 mice (Charles River Laboratories, Cologne,
Germany) were used for the study (Phenos GmbH, Hannover, Germany). Peritonitis
had been surgically induced under light isoflurane anesthesia. Incisions were made into
the left upper quadrant of the peritoneal cavity (normal location of the cecum). The
cecum was exposed and a tight ligature was placed around the cecum with sutures
distal to the insertion of the small bowel. One puncture wound was made with a 24-gauge
needle into the cecum, and small amounts of cecal contents were expressed through the
wound. The cecum was replaced into the peritoneal cavity and the laparotomy site was
closed. Finally, the animals were returned to their cages with free access to food and
water. Five hundred microliters of saline was given s.c. as fluid replacement.Efficacy test
Using this CLP model, three anti-mouse ADM antibodies (NT-M, MR-M, and CT-M)
were tested for their ability to modify the 14-day mortality rate in comparison to
vehicle (PBS buffer) and control compound (unspecific IgG). Ten animals per
compound were used. Compounds were applied i.v. immediately prior to surgery
(10 μL/g body weight, 0.2 mg/mL). Mice were monitored twice daily. In a follow-up
experiment, Fab- and F(ab)2 fragments of NT-M were tested analogously.Safety test
Twelve- to fifteen-week-old male C57Bl/6 mice (Charles River Laboratories, Germany)
were used for the study. Six mice were treated with NT-M anti-ADM antibody (10 μL/g
body weight; 3.0 mg/mL). As control, six mice were treated with PBS (10 μL/g body
weight). Survival and physical condition were monitored for 14 days.Ethics
For all animal experiments described in this manuscript, approval was obtained according
to the requirements of the respective German law (Tierschutzgesetz (TierSchG)) from the
Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit
(LAVES). Our study has been purely experimental and did not involve any human
samples.Statistics
Statistical significance was calculated by Student's t test. For survival analysis, Kaplan-Meier
curves were generated and log-rank test for significance was performed. GraphPad Prism 4
software (GraphPad Software, Inc., La Jolla, CA, USA) was used.
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Anti-ADM antibodies
Several mouse monoclonal antibodies against the N-terminal, midregional, and C-terminal
moieties of mouse ADM (NT-M, MR-M, CT-M) and human ADM (NT-H, MR-H, CT-H)
were developed (Figure 1, Table 1). The affinity constants of the antibodies were in the range
of 1.1 × 10−9 to 1.6 × 10−8 M (Table 1).
The agonist and antagonist activities of the antibodies were tested in an established
ADM bioassay system employing a CHO cell line overexpressing the human recombinant
ADM receptor (CRLR + RAMP3) with a cAMP readout. None of the antibodies exhibited
agonist activity in the bioassay (data not shown). The antibodies showed different
dose-dependent antagonist activity profiles (Figure 2, Table 1). Surprisingly, the
observed differences were dependent on the epitope specificity rather than on the
affinity of the antibodies, for both the anti-human ADM and the anti-mouse ADM
antibodies: The maximal obtainable inhibition of the ADM-induced cAMP response
was 100% for the antibodies directed against the C-terminal moiety of ADM, around 70%
for the antibodies directed against the midregional moiety of ADM, and around 25% for
the antibodies directed against the N-terminal moiety of ADM (Figure 2, Table 1).
The anti-mouse ADM antibodies were tested in a CLP sepsis mouse model for their
ability to reduce mortality. The observation period was 14 days. The doses of antibodies
were chosen so that concentrations in vivo should by far exceed on a molar basis
the expected concentrations of endogenous plasma ADM. In the control groups
(vehicle buffer or unspecific control antibody), most of the animals had died
already on day 1 (Figure 3). The antibodies against the midregion and C-terminus
of ADM improved survival slightly, but significantly, when compared to either vehicle or
control (MR-M vs. vehicle: HR = 0.182 (CI = 0.760 to 0.043), p = 0.0195; MR-M vs.
control: HR = 0.201 (CI = 0.051 to 0.789), p = 0.0215; CT-M vs. vehicle: HR = 0.182
(CI = 0.766 to 0.043), p = 0.0202; CT-M vs. control: HR = 0.1796 (CI = 0.044-0.733),
p = 0.0167). A strong and sustained improvement of survival was obtained with
the antibody against the N-terminus of ADM: 50% of the animals treated with this
antibody survived the CLP procedure over the observation period of 14 days (Figure 3)
(NT-M vs. vehicle: HR = 0.068 (CI = 0.291 to 0.0159), p = 0.0003; NT-M vs. control:
HR = 0.07717 (CI = 0.0189 to 0.315), p = 0.0004). The improvement of survival
for the antibody against the N-terminus of ADM was significantly higher than for the
anti-midregion and the anti-C-terminal antibody (NT-M vs. MR-M: HR = 0.212
(CI = 0.712 to 0.063), p = 0.0122; NT-M vs. CT-M: HR = 0.285 (CI = 0.0823 to 0.979),
p = 0.0462). Similar results were obtained in a follow-up experiment with Fab and10        20        30        40        50
Human YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQGY
::::::  :: :: :::::::: :::::::::.::::::..:::.:::::::
Mouse YRQSMN--QGSRSNGCRFGTCTFQKLAHQIYQLTDKDKDGMAPRNKISPQGY
10        20        30       40         50
Figure 1 Amino acid sequences of human and mouse Adrenomedullin. Monoclonal antibodies were
developed against peptides representing positions 1–21, 21–32 and 42–52 of human Adrenomedullin and
against peptides representing positions 1–19, 19–31, 40–50 of mouse Adrenomedullin.








































Figure 2 Dose/response curves for various anti-ADM antibodies affecting ADM-induced cAMP
response in an ADM bioassay (antagonist activity). The monoclonal antibodies used were directed
against the N-terminus (NT-M), mid-region (MR-M) and C-terminus (CT-M) of mouse ADM in the presence
of 0.67 nM mouse ADM (panel A), and directed against the N-terminus (NT-H), mid-region (MR-H) and
C-terminus (CT-H) of human ADM in the presence of 5.63 nM human ADM (panel B).
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HR = 0.273 (CI = 0.043 to 0.356), p = 0.0017; F(ab)2: HR = 0.298 (CI = 0.044 to
0.354), p = 0.0025). When the antibody against the N-terminus of ADM was
administered to healthy mice even at a 15-fold-higher concentration than that in
the CLP experiment, all animals survived and the physical condition of the animals
was not impaired compared to control animals (data not shown).
When the antibody against the N-terminus of ADM was administered to healthy
mice even at a 15-fold higher concentration than in the CLP experiment, all animals
survived and the physical condition of the animals was not impaired compared to
control animals (data not shown).Discussion
In this study, we report that an antibody directed against the N-terminus of ADM
substantially reduces mortality in a septic animal model, whereas antibodies againstFigure 3 Survival rates of CLP mice treated with various antibodies. The monoclonal antibodies used were
directed against the N-terminus (NT-M) (Panel A), and mid-region (MR-M) and C-terminus (CT-M) of mouse ADM
(Panel B). An unspecific mouse IgG was used as control (shown in Panels A and B). For statistics see main text.
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Figure 4 Survival rates of CLP mice treated with NT-M antibody fragments. Fab and F(ab)2 fragments of
the antibody directed against the N-terminus (NT-M) of ADM were tested. For statistics see main text.
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inhibit ADM agonist function in a bioassay.
It has been known that plasma ADM levels strongly increase with the severity of
sepsis, severe sepsis, and septic shock, and that elevated levels are highly prognostic for
fatal outcome [24-26]. This had suggested that ADM plays a role in the cascade of
events happening during the progression of sepsis, leaving open the question, though,
of whether ADM represents the ‘fire’ or the ‘firemen’, whether it is friend or foe in this
process. ADM has been shown to be a key player in initiating the hyperdynamic
response during the early stage of sepsis [12-14]. When sepsis proceeds to hypodynamic
shock, vascular responsiveness to ADM fades, suggesting that reduced ADM function
could be causal for progression of the disease. Consequently, supplementation of
exogenous ADM has been tested in animal models as a possibility to reduce mortality
from sepsis [12,18-21]. These attempts were successful. However, concerns have been
raised with respect to the safety of this approach as ADM, due to its strong vasodilatory
activity, might be harmful in certain situations, and thus, the therapeutic regime might be
difficult to control [27]. Additionally, ADM as a small peptide is prone to proteolytic
degradation and - as plasma protease activities increase and vary in sepsis patients [28] - it
might not be an ideal drug structure by concept. Moreover, at least the group of Wang is
convinced that ADM alone is not sufficiently efficacious, but coadministration of
complement factor H, an ADM binding protein, is necessary [12]. Development of such a
two-compound drug appears challenging in several aspects.
ADM might not be beneficial under all circumstances in the progression of
sepsis: In vitro experiments suggest that ADM has negative inotropic effects and
cause impairment of cardiac function in sepsis: The contractility of cardiac myocytes
isolated from LPS-treated rats was reduced compared to that in control animals, and
addition of ADM (22-52), an ADM receptor antagonist peptide, reversed this effect
[22]. With an anti-ADM antiserum, mortality of LPS-treated rats could be reduced
[22]. It was interpreted that during the progression of sepsis, the role of ADM
reverses from that of a compensatory mediator to a perpetuator of cardiodepression [29].
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not further characterized; no information was gained concerning the concentration
of anti-ADM antibodies in the antiserum, their affinities, their epitope specificities,
and their agonist and antagonist activities.
We set out to systematically develop and characterize monoclonal antibodies directed
against various epitopes of ADM and investigate their potential utility as drugs to
reduce sepsis-associated mortality in a mouse CLP model. Antibodies against the
C-terminal moiety of ADM were capable of fully inhibiting the ADM-induced
cAMP response in an ADM receptor bioassay. This could have been expected as
ADM (22-52) is known to be an effective ADM receptor antagonist. Less expected
was our finding that antibodies against the N-terminal moiety of ADM inhibited
ADM agonist activity maximally by only around 25%. The level of inhibition did
not change over almost three orders of magnitude of antibody concentration
tested. It was exactly such an anti-N-terminal antibody as well as Fab and F(ab)2
fragments thereof, which substantially reduced mortality in a mouse CLP model. In
contrast, an anti-C-terminal antibody did not strongly improve survival in this animal
model. Thus, promotion of survival apparently requires on one hand a certain minimum
level of functional ADM and on the other hand the reduction of excessively high
concentrations of ADM. It appears paradoxical that both supplementation with
ADM, as shown previously [12,18-21], and antibodies against ADM, as we show
here, can reduce mortality in septic animal models. We can only speculate about
the mechanistic background of these observations: As ADM has an in vivo half-life
of only 22 min [30], a relatively short increase of ADM levels, especially in the
early phase of sepsis progression, might be beneficial. The reduction of ADM functionality
by an anti-N-terminal antibody might be more relevant in the later phase, when excessive
endogenous ADM production is associated with fatal outcome. Our results indicate that
complete inhibition of ADM agonist activity during sepsis is not very efficacious, if at all,
to improve survival. The mechanism leading to a substantially improved survival rate of
CLP mice when treated with an anti-N-terminal antibody is not completely clear. We
hypothesize that binding of the anti-N-terminal antibody to ADM still allows receptor
binding, but less efficiently, and thus reduces the functionality of ADM so that excess
levels, which have been suggested to become harmful during the progression of sepsis,
then get functionally neutralized to a certain limited extent. Partial functional inhibition
of ADM, on the other hand, leaves sufficient ADM available, which is required in the early
hyperdynamic phase of sepsis and possibly later as well. It is not excluded that besides the
functional modulation of ADM, the anti-N-terminal antibody influences the proteolytic
decay of circulating ADM, since ADM is N-terminally susceptible to proteolytic degradation
[31], and thereby prolongs its half-life and bioavailablity. In any case, the use of a defined
anti-N-terminal antibody constitutes a novel approach to modulate the ADM pathway
during the progression of sepsis, which has some obvious advantages over previously
applied concepts involving ADM as a drug component: An antibody is less prone
to proteolytic degradation than ADM peptide; elevated and varying proteolytic activity
might in an uncontrolled manner affect peptide integrity in the circulation of
sepsis patients. ADM is a very sticky molecule [32], and this might add risk in the
drug production and application processes. Thirdly, concerns have been raised against the
use of ADM as a drug since it is known as a strong vasodilator, and thus it might be
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this window. In contrast, the anti-N-terminal antibody appears safe as it did not impair
healthy mice, even at a 15-fold-higher concentration than that successfully used in the
CLP model. Presumably, this is due to a relatively small modulation of the ADM system.
Finally, the development of monoclonal antibodies as drugs is a standard process
nowadays. If it turns out that, as Wang's group suggests, in fact complement factor H
must be coadministered with ADM to gain sufficient efficacy, then this represents
another challenge for drug development, which we do not face with the development of a
therapeutic antibody.Conclusions
In conclusion, we have shown in an established septic mouse model a strongly beneficial
effect on survival by use of an anti-N-terminal ADM antibody. The effect is due to its
epitope specificity and is associated with partial inhibition of ADM agonist function. The
results of this pilot study are a basis to further develop an alternative, advantageous way
for drug development modulating the ADM pathway to finally reduce mortality during
the progression of sepsis, which continues to be a strong unmet clinical need.Key messages
The following are the key messages derived from this study:
 Anti-ADM antibodies have different antagonist activity in vitro depending on their
epitope specificity.
 Antagonist activity is strong for anti-C-terminal antibodies, medium for anti-
midregional antibodies and weak for anti-N-terminal antibodies.
 Anti-ADM antibodies are significantly but differently efficacious in reducing
mortality in CLP-treated mice depending on their epitope specificity.
 The anti-N-terminal antibody reduces mortality substantially, whereas antibodies
against other regions of ADM are less potent.Abbreviations
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